SOURCE: Goldman Small Cap Research, Inc.

November 26, 2013 08:31 ET

Goldman Small Cap Research Initiates Research Coverage of Arrayit Corporation

BALTIMORE, MD--(Marketwired - Nov 26, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, announced today that it has initiated research coverage of Arrayit Corporation (OTCQB: ARYC), a life sciences and molecular diagnostics leader providing a huge suite of tools and integrated systems that empower scientists and clinicians to study all living things, from humans, animals, and plants, to viruses and bacteria.

Tracing its roots back to the mid-1990s, this microarray pioneer is poised to garner a meaningful share of the large and growing market. In fact, industry research firm Research Moz projects that the microarray industry will enjoy an 18% CAGR and reach the $11.4 billion mark in 2018. With 8 patent awards, Arrayit is one of the original innovators in the critical microarray field. ARYC's proprietary platform includes a huge suite of tools and integrated systems used by biopharma firms, research centers, diagnostic firms and others for study and analysis of genetic variation and biomedical functions.

Separately, Arrayit is prepping a novel ovarian cancer monitoring and screening diagnostic test, OvaDX®, for FDA 510(k) submission in early 2014. With no approved ovarian cancer tests in the market, an OvaDx® approval could lead to a very profitable new line of diagnostic products. Ovarian cancer is the 5th leading cause of cancer death in women, with over 22,000 women diagnosed in the U.S. each year.

In the Goldman Opportunity Research report on the Company, analyst Rob Goldman outlines his investment thesis.

"In addition to the value generated from the high growth and profitable core microarray tools and consumables business, and the huge potential of the ovarian cancer screening test, there is hidden value in the Company's intellectual property (IP), which has been successfully defended. Comparable companies have paid $90 million and up for similar IP portfolios. With high sales and earnings run rates, pending catalysts on the diagnostic test front, and the hidden IP value, we believe that Arrayit should command a premium valuation heading into 2014."

This press release contains excerpts of our most recently published research report on Arrayit Corporation. To view the sponsored research report, disclosures and disclaimers, or to download the report in its entirety, please visit

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit

About Arrayit Corporation (OTCQB: ARYC): Arrayit utilizes its patented and proprietary microarray platform to lead and empower the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure.

For more information, visit the Company's website:

Contact Information